The focus of pharmaceutical product development lies on assuring excellent product quality at the end of a cost-efficient process. The Quality-by-Design (QbD) concept shifts the focus from quality assurance through testing to quality control by process understanding, resulting in very robust processes with high quality product. QbD was originally intended by authorities for biologics, where product quality proven completely by analytics is not desired. Product quality has to be controlled by means of appropriate processes and operations as well.
Introduction
The positive effects of plants on human health have been used for centuries and are well accepted by patients to the present day. The efficacy of phytotherapeutics often results from a complex composition of substances [1, 2] . The complexity of plant-based drugs is one reason for the lack of satisfactory studies into their effect and causes problems for the definition and assurance of quality [3] . Although "good manufacturing practice" (GMP) is acknowledged as an important tool in quality assurance, the regulatory approach for most problems varies between the competent agencies (e.g. FDA, EMA) [4, 5] , which are responsible for the scientific evaluation of the market applications. In addition, more political support is needed to improve integration of traditional and complementary medicine into health systems [6] . The World Health Organization (WHO) recognizes these challenges and proposes a new strategy regulating traditional herbal medicines. [7] .
Quality assurance is realized by the implementation of GMP and is well established in the industry for all types of medicines [8] . The Food and Drug Administration (FDA) reviewed the regulatory approach to GMP practices at that time and introduced a modernized version with the focus on process risk determination, risk mitigation, and risk control to promote the development of robust and efficient processes [9] . This approach has been adopted and further developed by the European Medicines Agency (EMA) and other communities and culminates in the "Quality by Design" (QbD)-approach to process development for biologics. The QbD-approach in its current form is shown in Fig. 1 .
The implementation of QbD enables risk focused cooperation between competent agencies and manufacturers and offers a higher degree of process robustness and flexibility (see Fig. 2 ). Plants have in general a broad variety of compounds depending on growth and harvesting conditions. A suitable process design rated by the QbD principals ensures a robust process from extraction to purification even if the feedstock has a great variety. Over the last few years, a number of exemplary case studies have been published regarding different types of products [10] [11] [12] .
Also first commercial applications containing QbD-elements have been assessed and approved [13, 14] . QbD was originally intended by authorities for biologics, where product quality proven completely by analytics is not desired. Product quality has to be controlled by means of appropriate processes and operations as well.
These demands were developed in order to improve patients' safety by optimal drug quality at more efficient manufacturing processes reducing costs for healthcare systems. Furthermore, production of biologics includes feedstock variability and complex multi-step manufacturing processes in batch operation with variable lots -condition, which apply to botanicals as well.
Transferring the QbD-approach to botanicals the natural variability of plant material needs to be addressed, establishes a quality standard and offers increased process knowledge, three aspects with very high significance for herbal products [15] .
The focus on quality is important for phytopharmaceuticals, not only for the safety of patients, but to promote standardization and progress regarding the definition of quality of plant based products.
Example process
The spectrum of herbal products ranges from edible plants, general extracts to highly purified components, depending on the number and type of unit operation [16] . To cover the complete spectrum of products, the production of 10-deacetylbaccatin III (10-DAB) was chosen to showcase the methodical approach to process development including QbD-elements.
The development process consists of a series of steps, shown in Fig. 3 .
The QbD approach relies on solid process comprehension in order to control product quality throughout the process. Especially, the implementation of rigorous process models provides an effective method to establish the required process knowledge. They ensure comparability between process scales within rigorous models, which is why they represent the missing link, connecting process risk assessment and process characterization [17] [18] [19] .
A key concern regarding herbal products is the definition of quality. The QbD-approach demands a definition of quality coherent with the intended therapeutic application of the medication. The "quality target product profile" (QTTP) is based on pharmacodynamics and pharmacokinetic studies, as well as 
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